A national survey of knowledge, attitude, practice, and barriers towards pharmacovigilance and adverse drug reaction reporting among hospital pharmacy practitioners in the United Arab Emirates

Abstract

Abstract Background Pharmacovigilance (PV) is an essential component of patient safety and pharmacists are expected to be aware of the PV processes and willing to report ADRs. This study assessed the hospital pharmacists’ knowledge, attitude, and practice toward PV, barriers faced by them in ADR reporting, and factors influencing ADR reporting. Method A cross-sectional nationwide questionnaire survey was conducted among randomly chosen hospital pharmacists across UAE from March to July 2022. The filled questionnaires were assessed both descriptively [median (IQR scores), maximum 5 for Likert type and 1 for knowledge questions] and inferentially using the Mann–Whitney U test (for dichotomous variables) and the Kruskal–Wallis test (for variables with more than two responses) at alpha value = 0.05. Post hoc analyses and correlations were performed wherever applicable. Results Of the 342 respondents, the majority were knowledgeable about the concepts of PV (93.3%; n = 319) and ADRs (86.8%; n = 297). The overall median (IQR) knowledge score was 5 (3–7)/9. Knowledge levels within ‘qualification groups’ varied significantly (p-value < 0.001) and participants ‘between 10 and 14 years of experience’ had more knowledge than those ‘with < 5 years of experience’ (p-value < 0.001, Bonferroni test). The overall median (IQR) attitude score was 22 (20–24)/30. Most respondents (90.6%; n = 311) were willing to spare time to review patients’ ADR reports. The overall median (IQR) practice score was 17.5 (11–21)/24. Although 71.1% (n = 243) noticed ADRs during the previous year, only 53.2% (n = 182) reported an ADR, the reasons for underreporting being mainly due to a lack of proper training [median IQR score 4(4–5)/5]. The ‘clinical pharmacists’ engaged themselves more in pharmacovigilance than ‘pharmacists’ (p-value =  < 0.001), and ‘inpatient pharmacists’ reported more ADRs than ‘pharmacists’ (p-value = 0.018); Bonferroni test. The overall median (IQR) barrier score was 26 (23–29)/40 and the common barrier was ‘lack of awareness about the national ADR reporting system 4 (4–5)’. The pharmacists in this study suggested incentives for reporting ADRs (69.3%; n = 237). Conclusion The authors concluded professional training courses for practicing pharmacists and educational curriculums related to PV and ADR reporting processes are to be considered for future pharmacists in order to inculcate ADR reporting culture and practices.